Effect of 1 alpha-hydroxyvitamin D3 on loss of bone mineral density immediately after artificial menopause.
To evaluate the effects of 1 alpha-hydroxyvitamin D3 (1 alpha(OH)D3), a series of clinical trials, preventive and therapeutic, were performed in an open label manner in women immediately after oophorectomy. The series included a total of 121 oophorectomized subjects, whose lumbar bone mineral density (L2-4BMD) was followed by the use of dual energy X-ray absorptiometry. (1) Preventive trial: 61 women who had undergone premenopausal bilateral oophorectomy, were divided into 3 groups (Group C: control; Group L: 0.25 micrograms 1 alpha (OH)D3/day; Group H: 0.50-0.75 micrograms 1 alpha (OH)D3/day). The changes in BMD and chemical indices were followed up for one year. (2) Therapeutic trial: the trial included 60 premenopausally oophorectomized subjects having L2-4BMD lower than the normal control level minus 1SD which has been reported in age-matched normal Japanese women. These subjects were divided into 3 groups and treated in the same way as in the preventive trial. In the preventive trial, L2-4BMD decreased by 8.2%, 6.5% and 4.5% in groups C, L and H, respectively, at 12 months of treatment, whereas in the therapeutic trial, L2-4BMD decreased by 3.6%, 3.2% and 0.8% in the groups C, L and H, respectively, at 12 months of treatment. In conclusion, 1 alpha(OH)D3 was found to be effective both to prevent the bone loss subsequent to bilateral oophorectomy and improve low bone mass after oophorectomy.
Kato
T
T
Department of Gynecology, Cancer Institute Hospital, Tokyo, Japan.
Chen
J T
JT
Katase
K
K
Hirai
Y
Y
Hasumi
K
K
Ogata
E
E
Shiraki
Y
Y
Shiraki
M
M
D015519:Bone Density / Q000187:drug effects*; D001862:Bone Resorption / Q000188:drug therapy / Q000517:prevention & control; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D008593:Menopause / Q000187:drug effects / Q000378:metabolism*; D008875:Middle Aged; D010052:Ovariectomy / Q000009:adverse effects
D006887:Hydroxycholecalciferols; C008088:alfacalcidol